First in Human Study of TORL-1-23 in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Advanced Solid Tumor|Ovarian Cancer|Endometrial Cancer|NSCLC
DRUG: TORL-1-23
Incidence and severity of adverse events and serious adverse events, Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0, up to 2 years|Maximum Tolerated Dose (MTD), Highest administered dose with \< 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants, 28 Days|Recommended Phase 2 Dose (RP2D), Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data, up to 2 years
Objective Response Rate (ORR), Percentage of participants with best response of complete response (CR) or partial response (PR) according to RECIST 1.1, up to 2 years|Duration of Response (DOR), Time from CR or PR to objective disease progression or death to any cause, up to 2 years|Progression Free Survival (PFS), PFS is defined as the time from the start of the treatment until objective disease progression or death from any cause, up to 2 years|Time to Response (TTR), Time from start of treatment to complete response or partial response, up to 2 years|1 Year Overall Survival (1YOS), Proportion of participants alive at 1 year from the start of treatment to death from any cause, 1 year|2 Year Overall Survival (2YOS), Proportion of participants alive at 2 years from the start of treatment to death from any cause, 2 years|Number of anti-drug antibody (ADA) Positive Participants, Immunogenicity will be measured by the number of participants that are ADA positive., up to 2 years|Maximum Serum Concentration of TORL-1-23 (Cmax), PK assessment, 21 days|Minimum Serum Concentration of TORL-1-23 (Cmin), PK assessment, 21 days|Maximum Serum Concentration of TORL-1-23 at Steady State (Cmax,ss), PK assessment, 63 days|Minimum Serum Concentration of TORL-1-23 at Steady State (Cmin,ss), PK assessment, 63 days|Time of Maximum Serum Concentration of TORL-1-23 (Tmax), PK assessment, 21 days|Time of Minimum Serum Concentration of TORL-1-23 (Tmin), PK Assessment, 21 days|Time of Minimum Serum Concentration of TORL-1-23 at Steady State (Tmin,ss), PK Assessment, 63 days|Terminal Half-life (t1/2) of Serum TORL-1-23, PK Assessment, 63 days|Area under the Serum Concentration-Time curve from the time of dosing to the last measurable concentration (AUClast) for TORL-1-23, PK Assessment, 21 days|Area under the Serum Concentration-Time curve from the time of dosing extrapolated to time infinity (AUCinf) for TORL-1-23, PK Assessment, 63 days|Apparent volume of distribution during the terminal phase (Vz) of TORL-1-23, PK Assessment, 63 days|Clearance (CL) of TORL-1-23, PK Assessment, 63 days|Accumulation ratio (Rac) of TORL-1-23, PK Assessment, 63 days
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer